Exact Sciences (NASDAQ: EXAS) reported Q3 EPS of $0.24, $0.27 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $851 million versus the consensus estimate of $810.36 million.

GUIDANCE:

Exact Sciences sees FY2025 revenue of $3.22-3.235 billion, versus the consensus of $3.157 billion.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.